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Available online 18 July 2005644X-linked juvenile retinoschisis (RS) is a common cause of juvenile macular degeneration in males. RS
is characterized by cystic spoke-wheel-like maculopathy, peripheral schisis, and a negative (b-wave
more reduced than a-wave) electroretinogram (ERG). These symptoms are due to mutations in the
RS1 gene in Xp22.2 leading to loss of functional protein. No medical treatment is currently available.
We show here that in an Rs1h-deficient mouse model of human RS, delivery of the human RS1 cDNA
with an AAV vector restored expression of retinoschisin to both photoreceptors and the inner retina
essentially identical to that seen in wild-type mice. More importantly, unlike an earlier study with a
different AAV vector and promoter, this work shows for the first time that therapeutic gene delivery
using a highly specific AAV5–opsin promoter vector leads to progressive and significant improve-
ment in both retinal function (ERG) and morphology, with preservation of photoreceptor cells that,
without treatment, progressively degenerate.Key Words: retinoschisis, knockout mouse, gene therapy, AAV vector, electroretinogram,
opsin promoterINTRODUCTION
X-linked juvenile retinoschisis (RS) is a recessive degener-
ative disease of the central retina affecting only males with
a worldwide prevalence estimated at 1/5000–1/25,000 [1].
The disease may develop as early as infancy, but is more
often detected in boys between 5 and 10 years of age due to
reading difficulties in school. Affected individuals have a
relatively normal a-wave in the electroretinogram (ERG),
while the b-wave is nearly or totally absent. Another
hallmark of RS is the star-shaped schisis or splitting of the
inner retina, which develops primarily in the fovea, but
can also be present in the peripheral retina. These cystoid
cavities may coalesce, leading to further visual acuity loss.
Later in life, total vision loss can occur as a result of
associated complications such as retinal detachment,
vitreal hemorrhage, or choroidal sclerosis.The gene responsible for retinoschisis was identified by
positional cloning within chromosome band Xp22.2 [2]. It
consists of six exons and encodes a 224-amino-acid
protein that includes a 23-residue secretory leader
sequence. The encoded protein, termed RS1 or retinoschi-
sin, is secreted from both photoreceptors and bipolar cells
as a multimeric complex consisting of identical subunits
linked together by disulfide bonds [3–5]. Each subunit
consists of a single discoidin domain that has been
implicated in cellular adhesion and cell–cell interactions.
Currently, 133 different disease-causing mutations are
known, of which 111 are located within the discoidin
domain (http://www.dmd.nl/rs/). The effect of a number
of these mutations has been examined at a molecular and
cellular level [5,6]. Missense mutations in the discoidin
domain cause protein misfolding and retention of RS1 inMOLECULAR THERAPY Vol. 12, No. 4, October 2005
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IG. 1. RS1 expression in retinas of AAV-mOP-hRS1-injected and uninjected
yes. Retinal homogenates from treated and untreated eyes were separated
n a 10% SDS–polyacrylamide gel and the Western blot was probed with the
S1 3R10 monoclonal antibody. A single 24-kDa band corresponding to RS1
as detected in the AAV-mOP-hRS1-injected retinas, but not in the uninjected
ontralateral controls. The positions of prestained molecular mass markers (in
Da) are indicated on the left.
ARTICLEdoi:10.1016/j.ymthe.2005.06.002the endoplasmic reticulum (ER), while mutations in the
leader sequence prevent the translocation of the polypep-
tide chain across the ER membrane as part of the secretion
process. Mutations in cysteine residues flanking the
discoidin domain cause defective disulfide-linked subunit
assembly. In each case the mutant protein is unable to
function as an extracellular cell adhesion protein. Since
female carriers are unaffected, the absence of a functional
RS1 protein rather than the presence of a mutant protein is
responsible for RS in affected males.
To gain insight into the functional aspects of retino-
schisin, we generated a knockout (KO) mouse deficient in
Rs1h [7], the murine ortholog of the human retinoschisis
gene, RS1 [8]. The Rs1h-deficient mouse shares several
important diagnostic features with human RS, including
the typical negative ERG response, development of cystic
structures within the inner retina, and the loss of photo-
receptor cells [7,9]. Thus, the Rs1h KO mouse is a valuable
model for developing potential therapeutic interventions
for human RS. To explore this goal, we generated a
construct containing the human RS1 cDNA under the
control of the mouse opsin promoter in a recombinant
adeno-associated virus (AAV) serotype 5 vector and tested
it for therapeutic efficacy in Rs1h-deficient mice. We
show here that delivery of the human RS1 cDNA to Rs1h-
deficient mice using an AAV5–opsin promoter vector
restored the expression of retinoschisin to both photo-
receptors and the inner retina essentially identical to that
seen in wild-type mice. Moreover, unlike a previous study
in which a different AAV vector and promoter was used
[10], we provide evidence that the therapeutic gene
expression leads to both progressive and significant
improvement in retinal function (ERG) and morphology
with preservation of photoreceptor cells.
RESULTS
Vector-Mediated Expression of RS1 Leads to Improved
in Vivo Retinal Topography in the Rs1h-Deficient
Mouse
We delivered a capsid serotype 5 AAV vector containing
the wild-type human RS1 cDNA driven by a mouse opsin
promoter (AAV5-mOP-RS1) into the subretinal space of
the right eyes of Rs1h-deficient 15-day-old mice. Con-
tralateral left eyes were not injected and served as internal
controls. To confirm that AAV5-mOP-RS1 led to expres-
sion of the retinoschisin protein, we labeled a Western
blot of total protein from three pooled treated and
untreated retinas with a monoclonal antibody directed
against human RS1 [7]. The 24-kDa RS1-specific protein
band was present in the retinal extracts from the AAV5-
mOP-RS1-injected eyes, but absent in the contralateral
controls, indicating that retinoschisin expression occurs
upon treatment (Fig. 1).
In vivo analysis of retinal morphology with scanning-
laser ophthalmoscopy (SLO) revealed a prominent struc-MOLECULAR THERAPY Vol. 12, No. 4, October 2005
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ktural difference between treated and untreated eyes 6
months after injection (Fig. 2). The pathological pattern
of evenly distributed mottling originates from cyst
formation in the inner retina [7] and is clearly evident
in uninjected eyes (Fig. 2, right), whereas in treated eyes
the appearance of the inner retina is unremarkable in
regions where the vector was delivered, very similar to
wild type (Fig. 2, left and middle). A minor pigmentation
change surrounds the site of injection, indicative of a
small retinal detachment following injection (Fig. 2,
arrowheads).
Vector-Mediated Expression of RS1 Restores both
Rod- and Cone-Mediated ERG Responses in the
Rs1h-Deficient Mouse
To gain a preliminary impression of the functional
consequences of RS1 replacement, we followed the
maximum rod-mediated (scotopic) ERG amplitudes at
regular intervals for 3 months (Fig. 3). ERG b-wave
amplitudes in untreated eyes decline with time, confirm-
ing previous observations [7]. In contrast, delivery of
AAV5-mOP-RS1 vector reversed this trend and was able to
improve b-wave amplitudes at 2 and 3 months posttreat-
ment relative to 1 month. A similar trend was also
apparent for the rod-mediated a-wave with stable a-wave
amplitudes in treated retinas over the 3-month period.
We then carried out a more detailed electroretino-
graphic analysis on a separate cohort of animals treated
in one eye 5 months previously. Scotopic single-flash
ERG indicated a significant recovery of the negative ERG
waveform in treated versus untreated eyes (Figs. 4a and
4c). An increased b-wave was apparent at higher stimulus
intensities, with a modest increase in rod-mediated645
FIG. 2. In vivo imaging of AAV-mOPs-hRS1-
injected and uninjected eyes. 108 and 208
indicate the magnification of the fundus
photographs reflecting the instrument set-
ting. Red-free (514.5 nm) laser images
demonstrate the typical pattern of Rs1h-
deficient lesions in the uninjected eye (UE)
and the dramatic improvement in the
treated eyes (TE). The site of injection
(arrowhead) and the discoloration caused
by the postinjection changes are visible. The
extent of the treated area varied from
almost complete (left column) to about
40% (center column). In the latter case,
the border of the treated area is marked
with arrows.
ARTICLE doi:10.1016/j.ymthe.2005.06.002amplitudes in nearly all animals studied (Fig. 4e, left). An
even more pronounced effect of treatment was observed
in the light-adapted (photopic) single-flash ERG (Figs. 4b
and 4c) arising mainly from the recovery of oscillatory
potentials (OPs). The most prominent difference was
seen in the photopic flicker ERG (Figs. 4d and 4e). In
addition to improved OPs, responses to stimulus fre-
quencies above 3–5 Hz were greatly improved in treated
eyes.
Vector-Mediated Expression of RS1 Restores Normal
Retinal Distribution of RS1 Protein in the
Rs1h-Deficient Mouse and Corrects a Variety of
Retinal Structural Defects
To determine the treatment effect on the tissue
distribution of retinoschisin, we used a monoclonal
antibody to RS1 to label cryosections of retinas from 5-
month posttreatment retinas, untreated Rs1h-deficient
mouse retinas, and retinas of age-matched C57BL/6
wild-type mice. Patterns of RS1 labeling in injected
retinas were remarkably similar to those of wild-type
mice (Figs. 5a–5c). Photoreceptor inner segments
showed intense RS1 staining while outer nuclear and
outer plexiform layers were also labeled. There was
additional distinct immunostaining in the inner nuclear
(bipolar) layer and inner plexiform layer. Typically, only
the peripheral regions of the retina, distant from the
site of injection, exhibited a relative absence of RS1
labeling. Improvements in retinal structure were high-
lighted by differential interference contrast images
stained with DAPI nuclear dye (Figs. 5d–5f). Untreated
eyes showed pronounced disorganization at the zone
between inner and outer nuclear layers where numerous
gaps of various sizes within the bipolar cell layer were646evident. In contrast, treated eyes showed a distinct
separation of inner and outer nuclear layers similar to
that observed in wild-type retinas, an absence of gaps
between bipolar cells, and an increase in the thickness
of the outer nuclear layer. The outer nuclear layer of
the injected eye had an average of 10.5 F 1.0 photo-
receptor nuclei per column of cell bodies, whereas the
untreated contralateral retina had only 7.7 F 1.5 nuclei.
Treated retinas showed a narrow, well-defined band of
synaptophysin labeling of the photoreceptor–bipolar
synaptic region, whereas the untreated retina displayed
a much more irregular labeling pattern (Figs. 5g–5i).
Likewise, bipolar cells in treated retinas exhibited an
organized arrangement of cells akin to that of a wild-
type retina, whereas the untreated retinas displayed
bipolar cell disorganization (Figs. 5j–5l). GFAP, nor-
mally expressed at low levels in the basal region of
retinal Mqller cells [11], was markedly upregulated in
the untreated retina (Fig. 5o), consistent with obser-
vations associated with a variety of retinal lesions
[12,13]. Treated Rs1h-deficient retinas exhibited nearly
normal GFAP expression levels (Figs. 5m–5o). Addition-
ally, the thickness of the outer nuclear layer was greater in
the retinas of the treated eye compared to the untreated
eye (8.5 F 1.2 vs 6.9 F 0.8, n = 5). Preliminary studies
indicate that these structural improvements last more
than 1 year.
DISCUSSION
AAV-vectored RS1 restored both retinal integrity and
function in an Rs1h-deficient mouse model of human
RS. AAV-RS1 treatment not only partially corrected the
negative ERG, one of the hallmarks of both the RSMOLECULAR THERAPY Vol. 12, No. 4, October 2005
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FIG. 3. Preliminary electrophysiological response of AAV-mOP-RS1-injected
and uninjected eyes from RS1h-deficient mice. Simultaneous bilateral full-
field scotopic maximum ERG amplitudes in eyes of Rs1h-deficient mice at 1,
2, and 3 months postinjection. Bars represent mean amplitudes F SEM of
15, 15, and 15 eyes at 1, 2, and 3 months postinjection, respectively.
Normal ERG amplitudes of wild-type mice at comparable ages are shown
for comparison. P value between ‘‘KO, no vector‘‘ and ‘‘KO, vector‘‘ groups
was obtained with Student’s paired t test. Values are the averages of five
responses to a stimulus intensity of 0.173 log cd s m2 with a 1-min dark
interval between each recording. The values of a-wave amplitudes between
injected and uninjected eyes at 3 months postinjection are statistically
significant (184.9 F 17.5 AV vs 107.4 F 11.2 AV, P b 0.001). The values of
b-wave amplitudes between treated and untreated eyes are 257.7 F 18.2
AV vs 177.9 F 13.0 AV ( P b 0.001) at 2 months postinjection and 310.9 F
25.8 AV vs 162.6 F 15.3 AV ( P b 0.001) at 3 months postinjection,
respectively.
ARTICLEdoi:10.1016/j.ymthe.2005.06.002patient and the Rs1h-deficient mouse, but resulted in
improved visual function over approximately half the
lifetime of a mouse. The scotopic single-flash ERG
showed clear b-wave improvement, and even more
prominent photopic single-flash ERG recovery, with
the largest benefit seen in the flicker responses and
OPs. Since these ERG elements are each believed to
derive largely from postphotoreceptor responses, the
major therapeutic effect is suggested to involve func-
tional improvement in the inner retina. This correlates
well with both the histological findings and the results
of in vivo imaging demonstrating the structural improve-MOLECULAR THERAPY Vol. 12, No. 4, October 2005
Copyright C The American Society of Gene Therapyments and near elimination of inner retinal schisis
achieved by this treatment.
Onset of AAV5-RS1 expression in photoreceptors is
known to be fast, as early as 2 weeks after injection. It is
unclear at this stage why a peak of both a- and b-waves is
reached only 3 months after injection. We are currently
investigating the possibility that delivery of the thera-
peutic gene may be able to repair early stage retinoschisis
and this process may take time, thus explaining the delay
in reaching the maximum ERG response following
treatment.
The broadly distributive pattern of RS1 expression in
treated eyes is nearly identical to that seen in wild-type
mice. It suggests that retinoschisin, expressed either
naturally in wild-type mice or via an AAV vector in the
KO photoreceptors, is capable of moving longitudinally
and possibly also laterally within the retina to its
normal extracellular target sites. This observation con-
trasts with the preliminary work of Zeng et al. [10], who
employed a similar approach but used a different
mouse model and vector. They report high levels of
RS1 expression not only in photoreceptors but also in
ganglion cells after AAV2-cytomegalovirus (CMV)-RS1
treatment. This difference likely reflects different exper-
imental conditions, principally the AAV vector serotype
and promoter. Although serotype 2 and 5 vectors
transduce both photoreceptors and retinal pigmented
epithelium, the latter is much more efficient at trans-
ducing photoreceptors in the mouse retina than the
former when delivered into the subretinal space [14,15].
Furthermore, the specificity of AAV-mediated mouse
photoreceptor transduction is improved by replacing
the CMV promoter with the rod opsin promoter as was
done in our study [16]. In addition, it is well docu-
mented that serotype 2 AAV vectors transduce retinal
ganglion cells (RGC) upon intravitreal but not upon
subretinal injection [17,18]. Therefore, it is possible that
the RGC transduction noted by Zeng et al. [10] reflects
some leakage of vector into the vitreous space during
the subretinal injection. Given the photoreceptor spe-
cificity of expression with our AAV5–opsin promoter
vector, it is very likely that photoreceptors are the
primary source of RS1 for retina. It is also important to
note that in our study morphological recovery of the
inner retina and photoreceptors accompanies improve-
ment in visual function. This observation contrasts
with the previous study [10], in which improvement
of retinal function was not accompanied by corre-
sponding changes in retinal morphology. Perhaps the
potentially higher levels of RS1 related to our selection
of AAV serotype and promoter account for this key
difference.
In conclusion, the present study demonstrates that
gene therapy can effectively restore visual function in an
Rs1h-deficient mouse for at least 5 months postinjection.
This visual improvement is linked to the recovery of647
FIG. 4. Electrophysiological evaluation of AAV-mOP-hRS1-injected and uninjected eyes from RS1h-deficient mice at 5 months posttreatment. (a) Scotopic (dark-adapted) intensity series of a treated
animal. Differences between the treated and the untreated eye are apparent mainly at higher flash intensities, illustrating the recovery from the negative ERG waveform shape. (b) Photopic (light
adapted) intensity series of a treated animal. Differences between the treated and the untreated eye are more pronounced due to the strongly reduced or lacking oscillatory potentials in the untreated
eye. (c) Overlay of selected scotopic (top) and photopic (bottom) waveforms from the intensity series of a treated animal to illustrate differences in waveform between the treated and the untreated eye.
(d) Photopic flicker series of a treated animal. Prominent differences between the treated and the untreated eye are seen, indicating a recovery particularly for frequencies above 3–5 Hz. (e) Dark-adapted
(SC) and light-adapted (PH) b-wave and flicker amplitudes from treated eyes as a function of the logarithm of the flash intensity and the flicker frequency, respectively. In both graphs, data from the
treated eyes are given as box-and-whisker plots showing 5 and 95% quantiles (whiskers), 25 and 75% quartiles (box), and the median (marked by a cross). The red lines delimit the range given by the 5
and 95% quantile of the untreated eyes.
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FIG. 5. Immunofluorescence microscopy of retinas from AAV-mOP-hRS1-injected and uninjected Rs1h-deficient mice at 5 months posttreatment. Retinal
cryosections were (a–c) labeled with the RS1 3R10 monoclonal antibody and (d–f) stained with DAPI nuclear stain (blue) and imaged with differential
interference contrast microscopy, (g–i) labeled with SVP38 monoclonal antibody to synaptophysin, (j–l) labeled with the 115A10 monoclonal antibody to
bipolar cells and stained with anti-GFAP (m–o) to assess the Mu¨ller cell response to retinal lesions. Immunolabeling was visualized using Alexa 488-conjugated
goat-anti-mouse Ig. Arrows show gaps present in the untreated Rs1h-deficient mice. rpe, retinal pigment epithelium; os, outer segment; is, inner segment; onl,
outer nuclear layer; opl, outer plexiform layer; inl, inner nuclear layer; ipl, inner plexiform layer; gcl, ganglion cell layer.
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ARTICLE doi:10.1016/j.ymthe.2005.06.002impaired retinal morphology within both the inner and
the outer retinal layers. In preliminary results, such
functional and structural recovery persists for a longer
period.
MATERIALS AND METHODS
Rs1h-Deficient Animals
The Rs1h knockout mouse has been previously described [7]. Since then,
the targeted Rs1h gene has been bred for 10 generations onto a
CB57BL/6 background. Heterozygous Rs1h animals were inbred to
generate either homozygous Rs1h females or hemizygous Rs1h/Y males.
Rs1h-ko mice were screened by pcr amplification using tail dna as the
template, with two sets of oligonucleotide primers. one set (5V-TGAG-
GACCCCTGGTACCAGAA-3V, 5V-CCATCTCAGGCAAGCCAGG-3V) was
designed to amplify the wild-type Rsh1 gene, targeting exon 3 with a
product size of 260 bp. The same 5Vprimer, in combination with a 3V
primer (5V-CAAGGCGATTAAGTTGGGTAAC-3V) targeting LacZ was used
to detect the mutant Rs1h gene with a product size of 180 bp. A total of
15 Rs1h-deficient mice were used in this study. The animals were reared
under standard laboratory conditions (22 F 28C, 60 F 10% relative
humidity, and a 12-h light–dark cycle) and had free access to food and
water throughout the experiment. C57BL/6 wild-type mice used as
controls were obtained from The Jackson Laboratory (Bar Harbor, ME,
USA). The conditions of housing and experiments were in accordance with
the ARVO Statement for the Use of Animals in Ophthalmic and Vision Research
using protocols approved by the University of Florida Institutional Animal
Care and Use Committee.
Construction of an AAV Vector Expressing Human RS1
A cDNA encoding the full-length human RS1 was initially cloned into the
vector pBlueScript and then recloned into a pTR-AAV plasmid and
includes AAV inverted terminal repeats; a proximal mouse opsin
promoter (mOP-500), which restricts expression to photoreceptors; and
the human RS1 cDNA. Titers of AAV serotype 5 vectors were adjusted to 4
 1013 vector genomes/ml. Ratios of physical to infectious particles were
all lower than 100. For the production of the vector, a mini-Ad helper
plasmid pDG was used to produce AAV vector with no detectable
adenovirus or wild-type AAV contamination. AAV vector, purified using
iodixanol gradient/HI-Q FPLC chromatography, was more than 99%
pure, as determined by polyacrylamide silver-stained gel electrophoresis.
Further purification information has been described previously [19,20].
Subretinal Injection
Mice were subretinally injected with AAV-mOP500-hRS1 when they
were 15 days of age. After anesthesia with ip Ketamine (66.7 mg/kg)/
Xylazine (11.7 mg/kg), the right eye of each mouse was dilated with
1% atropine sulfate and 2.5% phenylephrine hydrochloride. After 2.5%
hydroxypropyl methylcellulose (Eye Supply USA, Tampa, FL, USA) was
applied to the cornea it was punctured carefully with a 30G1/2-gauge
needle guided by an operating microscope to avoid lens damage. A
blunt 33-gauge needle (Hamilton, Reno, NV, USA) was then inserted
through the corneal hole, maneuvered around the lens, displacing it
medially, and directed toward the subretinal space of the inferior
hemisphere. A total of 1 Al volume of vector with fluorescein tracer
(0.1 mg/ml) was used for each injection. An antibiotic (Vetropolycin,
Pharmaderm, NY, USA) was applied daily to the cornea for 3 days
following the procedure.
Western Blot Analysis
Retinas were dissected from three male RS1-KO mice at 3 months
postinjection, pooled into separate groups (injected and uninjected,
respectively), and homogenized by sonication in a buffer containing
0.23 M sucrose, 2 mM EDTA, 5 mM Tris–HCl (pH 7.5), 0.1 mM
phenylmethylsulfonyl fluoride. The samples were centrifuged at
16,000g for 10 min and the supernatants were collected. Protein
concentrations were determined using the Coomassie Plus protein
assay kit (Pierce, Rockford, IL, USA). After the addition of loading650buffer (100 mM Tris–HCl, pH 6.8, 4% SDS, 20% glycerol, 200 mM
dithiothreitol, 0.02% bromophenol blue), equal amounts (25 Ag) of
each sample were resolved by SDS–PAGE (10% Tris–glycine gel) and
electrotransferred to a polyvinylidene difluoride membrane (Immobi-
lon P; Millipore, Bedford, MA, USA). The membrane was blocked in
5% horse serum in PBS for 1 h at room temperature and incubated
overnight with mouse monoclonal antibody 3R10 specific for RS1
protein [7]. The blot was washed three times in PBS containing 0.05%
Tween 20 (PBST) and incubated with an anti-mouse IgG-conjugated
alkaline phosphatase secondary antibody for 30 min at room temper-
ature. After being washed again three times in PBST, the blot was
developed with a color assay using nitroblue tetrazolium and 5-bromo-
4-chloro-3-indolyl phosphate.
Scanning-Laser Ophthalmoscopy
Imaging was performed with a Heidelberg retina angiograph (Heidel-
berg Engineering GmbH, Dossenheim, Germany), a confocal SLO that
provides two laser wavelengths for fundus visualization (argon green,
514 nm, and infrared, 835 nm) and two laser wavelengths for
angiography (argon blue, 488 nm (barrier 500 nm) for fluorescence
angiography, and infrared, 795 nm (barrier 810 nm) for indocyanine
green angiography).
Electroretinographic Analysis
For preliminary time-course experiments, a UTAS-E 200 visual electro-
diagnostic system (LKC Technologies, Gaithersburg, MD, USA) was
employed. Detailed information on the protocol has been previously
described [21]. Briefly, mice were dark-adapted overnight and placed
under dim red illumination (N650 nm). Dark-adapted animals were
anesthetized and the pupils dilated as above. ERGs from both eyes
were recorded simultaneously. Gold contact lens electrodes were
placed on the eyes with a drop of 2.5% hydroxypropyl methylcellu-
lose (Eye Supply USA). A reference electrode was placed subcuta-
neously on the head and a ground electrode was placed in the right
hind leg. ERGs were recorded at stimulus intensities of 104, 102,
and 3 cd s/m2 with 10-, 30-, and 60-s interstimulus intervals (ISIs),
respectively, between stimulus flashes. Initial ERG analysis at 1 month
postinjection showed scotopic ERG impact only at the highest intensity.
Thus, this intensity was used throughout the remaining experiments. Five
ERG recordings were averaged for each recording at each stimulus. ERG
measurements were made at 1, 2, and 3 months postinjection with
statistical comparison between injected and uninjected eyes being done
using the Student paired t test.
For more detailed analysis at 5 months posttreatment, ERGs were
obtained according to previously reported procedures [22] in anesthe-
tized mice. The ERG equipment consisted of a Ganzfeld bowl, a DC
amplifier, and a PC-based control and recording unit (Toennies Multi-
liner Vision, Viasys Healthcare, Hoechberg, Germany). Band-pass filter
cut-off frequencies were 0.1 and 3000 Hz. Single-flash recordings were
obtained under both dark-adapted (scotopic) and light-adapted (pho-
topic) conditions. Light adaptation before the photopic session was
performed with a background illumination of 30 cd/m2 for 10 min.
Single-flash stimulus intensities were increased from 104 to 25 cd s/m2,
divided into 10 steps of 0.5 and 1 log cd s/m2. Ten responses were
averaged with ISIs of either 5 or 17 s (for 1, 3, 10, and 25 cd s/m2). Flicker
stimuli had an intensity of 3 cd s/m2 with frequencies of 0.5, 1, 2, 3, 5,
10, 15, and 30 Hz.
Immunofluorescence Labeling of Retinal Sections
Antibodies. Cell-specific antibodies used were monoclonal antibodies
RS1-3R10 to human RS1 protein [7], 115A10 (ROB) made against rat
olfactory bulb (kindly provided by Shinobu C. Fujita, Mitsubishi Kasei
Institute of Life Sciences, Tokyo, Japan.), Per 5H2 to peripherin/rds [23],
rabbit polyclonal anti-GFAP (dilution 1:200; Sigma–Aldrich, Munich,
Germany), and SYP (SVP38) against synaptophysin purchased from Santa
Cruz Biotechnology (Santa Cruz, CA, USA).
Immunolabeling. Retinas from injected and uninjected eyes of Rs1h-
deficient mice 5 month posttreatment and age-matched wild-type
C57BL/6 mice were used for immunocytochemical labeling studies.MOLECULAR THERAPY Vol. 12, No. 4, October 2005
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buffer (pH 7.4) for 4 h and subsequently rinsed in 0.1 M phosphate buffer
containing 10% sucrose. Cryosections were permeabilized and blocked
with PBS containing 0.2% Triton X-100 and 10% normal goat serum for
20 min and labeled overnight with the primary antibody diluted in PBS
containing 0.1% Triton X-100 and 2.5% normal goat serum. Sections
were rinsed in PBS containing 0.01% Tween 20 and labeled for 1 h with
Alexa 488-conjugated goat anti-mouse immunoglobulin (Molecular
Probes, Eugene, OR, USA). Labeled sections were also stained with DAPI
nuclear stain and examined under a Zeiss LSM510 confocal microscope
and processed with Zeiss LSM5 Image Browser. Counting of labeled cells
was carried out on a Zeiss Axioplan 2 fluorescence microscope equipped
with Northern Eclipse digital image analysis system.
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